Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening

Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening

Bibliographic Details
Main Authors:	Martin, RM, Dixon, PC, Turner, E, Keeney, E
Format:	Journal article
Language:	English
Published:	Wiley 2022

Similar Items

Prostate cancer: estimating the benefits of PSA screening.
by: Vickers, A, et al.
Published: (2009)

Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP randomized clinical trial
by: Martin, RM, et al.
Published: (2018)

Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
by: Thorn, J, et al.
Published: (2016)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
by: Bangma, C, et al.
Published: (2010)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
by: Denmeade, SR, et al.
Published: (2003)

Blue Cap Relay Run for Prostate Cancer®
by: Sothilingam, S., et al.
Published: (2016)

Quantitative PSA RT-PCR for preoperative staging of prostate cancer.
by: Kurek, R, et al.
Published: (2003)

Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.
by: Wiklund, F, et al.
Published: (2009)

Can PSA velocity predict risk of death in men with prostate cancer?
by: Lilja, H, et al.
Published: (2007)

Screening for prostate cancer.
by: Carlsson, S, et al.
Published: (2012)

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
by: Roobol, M, et al.
Published: (2009)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
by: Rosario, D, et al.
Published: (2008)

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level.
by: Törnblom, M, et al.
Published: (2001)

Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer.
by: Lilja, H
Published: (2001)

Uji diagnostik prostate spesific antigen (PSA) pada keganasan prostat
by: , DAHESIHDEWI, Andaru, et al.
Published: (2002)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
by: Lane, J, et al.
Published: (2010)

Prostate cancer /
by: 375298 Cramer, Scott D.
Published: (2007)

Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancer.
by: Lilja, H
Published: (2008)

Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.
by: Roddam, A, et al.
Published: (2005)

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section.
by: Khatami, A, et al.
Published: (2007)

ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING
by: Burton, A, et al.
Published: (2011)

We need a better marker for prostate cancer. How about renaming PSA?
by: Vickers, A, et al.
Published: (2012)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
by: Burton, A, et al.
Published: (2013)

Survival and PSA relapse data after hypofiractionated radiotherapy for early stage prostate cancer
by: Law, A, et al.
Published: (2007)

A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer
by: Srinivasan, S, et al.
Published: (2024)

Prostate cancer: screening approaches.
by: Donovan, J, et al.
Published: (2005)

Screening for prostate cancer: an update.
by: Bryant, R, et al.
Published: (2008)

Screening for prostate cancer: To the editor
by: Carlsson, S, et al.
Published: (2012)

Prostate cancer: screening approaches
by: Donovan, J, et al.
Published: (2005)

Screening for prostate cancer: an update.
by: Shariat, S, et al.
Published: (2008)

PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK
by: Brett, J, et al.
Published: (2005)

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen
by: Harrison, S, et al.
Published: (2020)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.
by: Roobol, M, et al.
Published: (2012)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.
by: Catto, J, et al.
Published: (2011)

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study
by: Catto, J, et al.
Published: (2011)

Qualitative and quantitative PSA mRNA detection in prostate cancer - A useful tool for the clinician?
by: Phillips, J, et al.
Published: (2007)

Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA.
by: Sävblom, C, et al.
Published: (2009)

Report of the forth Asian Prostate Cancer (A-CaP) study meeting
by: Youl Lee, Ji, et al.
Published: (2019)

The epidemiology of hormones and prostate cancer
by: Watts, E
Published: (2019)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
by: Becker, C, et al.
Published: (2001)